Skip to main content
Clinical Trials/NCT04997525
NCT04997525
Completed
Phase 4

Estradiol and Progesterone Levels in Early Pregnancy After Natural, Estradiol + Progesterone or Gonadotrophin Stimulated Frozen Embryo Transfer Cycle

Copenhagen University Hospital at Herlev1 site in 1 country305 target enrollmentApril 20, 2021

Overview

Phase
Phase 4
Intervention
Chorionic Gonadotropin, Alpha
Conditions
Infertility
Sponsor
Copenhagen University Hospital at Herlev
Enrollment
305
Locations
1
Primary Endpoint
Serum estradiol
Status
Completed
Last Updated
last year

Overview

Brief Summary

The aim of the present study is to investigate serum estradiol and progesterone levels in women conceiving after natural, estradiol + progesterone or gonadotropin stimulated frozen embryo transfer (FET) cycles.

Detailed Description

Enrolled women will be randomized based on their ovulation pattern. Ovulatory women will be randomized to either natural cycle or estradiol + progesterone substituted cycle treatment for FET. Anovulatory women will be randomized to either estradiol + progesterone substituted cycle or gonadotropin stimulated cycle treatment for FET. Included women will undergo blood testing every two weeks for serum estradiol and progesterone levels until gestational age 9+6. Routine vaginal ultrasounds will be performed as well as additional pregnancy ultrasounds. Secondary obstetric outcomes will be investigated using the womens medical journals. All the treatments are considered standard treatments for FET.

Registry
clinicaltrials.gov
Start Date
April 20, 2021
End Date
December 6, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Copenhagen University Hospital at Herlev
Responsible Party
Principal Investigator
Principal Investigator

Pernille Fog Svendsen, DMSc

DMSc

Copenhagen University Hospital at Herlev

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 years \< 40 years
  • BMI \< 35 kg/m2
  • Normal wet smear within the past three years
  • Thawed blastocysts (day 5 or 6) after either IVF or ICSI treatment

Exclusion Criteria

  • Age \< 18 years
  • BMI \> 35 kg/m2
  • Oocyte donation
  • HIV/ hepatitis
  • Undiagnosed vaginal bleeding
  • Uterine malformations
  • Persisting ovarian cysts
  • Tumors in Hypothalamus, pituitary, thyroid or adrenal
  • Previous breast cancer
  • Unregulated thyroid disease

Arms & Interventions

Natural cycle

These women will follow their natural cycle and receive one injection of hCG for stimulation of ovulation before embryo transfer

Intervention: Chorionic Gonadotropin, Alpha

Estradiol and progesterone

These women will receive daily estradiol and progesterone tablets/capsules before and after embryo transfer. Treatment will continue until gestational age 9+6

Intervention: Estradiol Tablets

Estradiol and progesterone

These women will receive daily estradiol and progesterone tablets/capsules before and after embryo transfer. Treatment will continue until gestational age 9+6

Intervention: Progesterone

Gonadotropin

These women will receive daily gonadotropin injection before embryo transfer. Ovulation will be stimulated using hCG injection.

Intervention: Follitropin Alfa

Gonadotropin

These women will receive daily gonadotropin injection before embryo transfer. Ovulation will be stimulated using hCG injection.

Intervention: Chorionic Gonadotropin, Alpha

Outcomes

Primary Outcomes

Serum estradiol

Time Frame: 10 weeks

Blood samples in the first 10 weeks of pregnancy

Serum progesterone

Time Frame: 10 weeks

Blood samples in the first 10 weeks of pregnancy

Secondary Outcomes

  • Child malformations(9 months)
  • Obstetric complications(9 months)
  • Child birth weight(At delivery)
  • Gestational age at delivery(At delivery)

Study Sites (1)

Loading locations...

Similar Trials